 Silence Therapeutics PLC LON:SLN, NASDAQ:SLN said its medics and scientist has contributed to a peer-reviewed paper that explores the promising potential RNA interference RNAi therapies for treating heart disease. RNAi is a natural process that works almost like a dimmer switch to dial down the level of a protein. 